Please check your internet connection and try again.
## Sodium Phosphate Enema
### Overview
Sodium phosphate enema is a hypertonic saline solution used as a laxative for bowel preparation and constipation relief.
### Primary Indications
* Bowel cleansing prior to colonoscopy or surgery.
* Relief of occasional constipation.
### Adult Dosing
* **Bowel Preparation:** Typically, one 4.5 fl oz (133 mL) enema administered 2-5 hours before the procedure. Repeat dose may be required based on protocol.
* **Constipation Relief:** One 2.25 fl oz (66 mL) enema administered once daily, as needed.
### Pediatric Dosing
* **Under 2 years:** Not recommended.
* **2-5 years:** 1.125 fl oz (33 mL) enema once daily.
* **6-11 years:** 2.25 fl oz (66 mL) enema once daily.
* **12 years and older:** Adult dosing.
### Dose Adjustments
* No specific dose adjustments for hepatic or renal impairment are established for enema use. Caution is advised due to potential for electrolyte imbalance.
### Contraindications
* Congenital megacolon.
* Congestive heart failure.
* Renal insufficiency.
* Anuria.
* Intestinal obstruction.
* Acute bowel obstruction.
* Children less than 2 years of age.
* Patients with impaired electrolyte absorption.
* Concurrent use of other sodium-phosphate bowel preparations.
### Adverse Effects
* Most common: Abdominal cramping, nausea, vomiting, bloating, rectal irritation.
* Serious: Hyperphosphatemia, hypocalcemia, hypernatremia, metabolic acidosis, dehydration, acute kidney injury, cardiac arrhythmias. Risk is increased in patients with pre-existing renal disease or those who use the product excessively or incorrectly.
### Key Drug Interactions
* **Diuretics (thiazide, loop):** Increased risk of electrolyte abnormalities.
* **ACE inhibitors/ARBs:** Increased risk of hyperkalemia and electrolyte imbalances.
* **NSAIDs:** May increase the risk of renal toxicity.
### Monitoring
* Monitor for signs and symptoms of dehydration and electrolyte imbalance (e.g., dizziness, decreased urination, muscle cramps, confusion, irregular heartbeat).
* Monitor renal function and electrolytes in patients with risk factors.
### Clinical Pearls
* Ensure adequate fluid intake before and after administration.
* Avoid use in elderly patients, patients with renal impairment, or those with existing electrolyte abnormalities due to the risk of severe hyperphosphatemia and hypocalcemia.
* Do not use in children under 2 years of age.
* Do not use for more than one week.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and local protocols for definitive guidance.*
